The expression levels and clinical significance of serum miR-132-3p and SMAD2 in patients with Alzheimer's disease
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
国家科技期刊平台
NETL
NSTL
万方数据
目的 探讨微小RNA-132-3p(miR-132-3p)、SMAD2在阿尔茨海默病(AD)患者预后中的价值.方法 收集2020年1月-2022年12月佳木斯市中心医院神经内科治疗的AD患者82例作为研究对象,根据6个月后预后情况分为预后良好组39例和预后不良组43例,记录患者基线资料.采用实时荧光定量PCR(qRT-PCR)法检测血清miR-132-3p水平,采用酶联免疫吸附法检测血清SMAD2水平;采用Pearson及Spearman相关性分析检验预后不良AD患者miR-132-3p、SMAD2水平与基线资料的相关性;采用受试者工作特征(ROC)曲线分析血清miR-132-3p、SMAD2水平对AD患者预后不良的预测价值;采用Logistic多因素回归分析AD患者预后不良的影响因素.结果 预后不良组血清SMAD2水平及AD分期中/晚期比例、CRP、Hcy高于预后良好组,血清miR-132-3p水平、HDL-C低于预后良好组(t/x2/P=7.362/＜0.001、5.598/0.018、14.021/＜0.001、12.593/＜0.001、7.145/＜0.001、6.655/＜0.001).预后不良AD患者血清miR-132-3p与AD分期、CRP、Hey呈负相关,与HDL-C呈正相关(r=-0.513、-0.492、-0.507、0.485,P＜0.001);预后不良 AD 患者血清 SMAD2 与 AD 分期、CRP、Hcy 呈正相关,与HDL-C 呈负相关(r=0.504、0.527、0.510、-0.496,P＜0.001).血清 miR-132-3p、SMAD2 单独及二者联合预测 AD 患者预后不良的AUC分别为0.828、0.835、0.910,二者联合预测价值大于二者单独检测(Z=2.148、1.964,P=0.032、0.046).AD分期中/晚期、SMAD2高是影响AD患者预后不良的独立危险因素[OR(95％CI)=2.978(1.609～5.511)、2.826(1.776～4.497)],miR-132-3p 高是影响 AD 患者预后不良的保护因素[OR(95％CI)=0.828(0.722～0.950)].结论 预后不良AD患者血清miR-132-3p表达降低,SMAD2表达升高,二者可能成为AD患者预后不良的血清标志物.
Objective To explore the prognostic value of microRNA-132-3p(miR-132-3p)and SMAD2 in patients with Alzheimer's disease(AD).Methods From January 2020 to December 2022,82 AD patients treated in Department of Neurology,Jiamusi Central Hospital were collected as research subjects,according to the prognosis after 6 months,they were grouped into a good prognosis group(39 cases)and a poor prognosis group(43 cases),the baseline data of the pa-tient were recorded.Real-time fluorescence quantitative PCR(qRT-PCR)method was applied to detect serum levels of miR-132-3p,enzyme-linked immunosorbent assay was applied to detect serum levels of SMAD2;Pearson and Spearman correla-tions were applied to analyze and test the correlation between miR-132-3p,SMAD2 levels and baseline data in AD patients with poor prognosis;ROC curve was applied to analyze the predictive value of serum miR-132-3p and SMAD2 levels for poor prognosis in AD patients;Logistic multiple factor regression was applied to analyze the influencing factors of poor prognosis in AD patients.Results Serum levels of SMAD2 and the proportion of mid/late stage AD,CRP,and Hey in the poor prognosis group were higher than those in the good prognosis group,while serum levels of miR-132-3p,and HDL-C were lower than those in the good prognosis group(t/x2=7.362,5598,14.021,12.593,7.145,6.655,P＜0.05).MiR-132-3p in AD patients with poor prognosis was negatively correlated with AD staging,CRP,Hcy,and positively correlated with HDL-C(r=-0.513,-0.492,-0.507,0.485,P＜0.001);SMAD2 in AD patients with poor prognosis was positively correlated with AD stage,CRP,Hcy,and negatively correlated with HDL-C(r=0.504,0.527,0.510,-0.496,P＜0.001).The AUC of ser-um miR-132-3p and SMAD2 alone and in combination for predicting poor prognosis in AD patients was 0.828,0.835,and 0.910,the combined predictive value of the two is greater than that of the two alone(Z=2.148,1.964,P=0.032,0.046).AD staging was an independent risk factor for poor prognosis in AD patients,and miR-132-3p were protective factors for poor prognosis in AD patients,SMAD2 is an independent risk factor for poor prognosis in AD patients(OR:95％CI=2.978(1.609-5511),P=0.001;OR:95％CI=0.828(0.722-0.950),P=0.007;OR:95％CI=2.826(1.776-4.497),P＜0.001).Conclu-sion The expression of miR-132-3p is reduced in AD patients with poor prognosis,the expression of SMAD2 is increased,and they may become serum markers of poor prognosis in AD patients,which can to some extent predict the development of the disease in AD patients.
国家科技期刊平台
NSTL
万方数据
